SCRIP
CITELINE COMMERCIAL

11 Oct 2023 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Lilly’s radiopharmaceutical buy; strong third quarter for biotech financing; Novartis’s nephropathy results; US ICER runs cost analysis on first batch of drugs; and the outlook for US FTC oversight of biopharma M&A.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 October 2023, including: *Eli Lilly and Company*’s radiopharmaceutical buy; strong third quarter for biotech financing; *Novartis AG*’s nephropathy results; US ICER runs cost analysis on first batch of drugs; and the outlook for US FTC oversight of biopharma M&A.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space*" - Scrip, 3 Oct, 2023.)

(Also see "*Biotech IPOs Get Bigger, But Not Necessarily Better*" - Scrip, 4 Oct, 2023.)

(Also see "*Muted APPLAUSE For Novartis In IgAN*" - Scrip, 2 Oct, 2023.)

(Also see "*ICER Hands CMS A Drug Price Negotiation Cheat Sheet*" - Scrip, 2 Oct, 2023.)

(Also see "*Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?*" - Scrip, 3 Oct,

SCRIP
CITELINE COMMERCIAL

2023.)

Click here to explore this interactive content online